ROCHE-BO18255 (ToGA)

Study Sponsor : Roche

Study Title

An open-label randomized multicentre Phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2-positive advanced gastric cancer.

Medicine or Vaccine (generic name)

trastuzumab

Sponsor Identification Number

BO18255 (ToGA)

Trial Registry Identification Number(#'s)

NCT01041404

Medical Condition

HER2-positive metastatic breast cancer

Phase

Phase 3

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/ct2/show/NCT01041404

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

January 2014